|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019704,
umls-concept:C0021311,
umls-concept:C0030705,
umls-concept:C0036043,
umls-concept:C0087111,
umls-concept:C0205390,
umls-concept:C0439230,
umls-concept:C0439611,
umls-concept:C1314939,
umls-concept:C1456409,
umls-concept:C2603343
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2008-9-9
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Etravirine (ETR; also known as TMC125) is a new nonnucleoside reverse-transcriptase inhibitor with activity against wild-type and nonnucleoside reverse-transcriptase inhibitor-resistant human immunodeficiency virus type 1 (HIV-1).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1537-6591
|
|
pubmed:author |
pubmed-author:ClumeckNathan NNN,
pubmed-author:FätkenheuerGerdG,
pubmed-author:GatellJoseJ,
pubmed-author:HayPhillipP,
pubmed-author:MontanerJulioJ,
pubmed-author:PeetersMonika PMP,
pubmed-author:Schöller-GyüreMonikaM,
pubmed-author:SeminariElenaE,
pubmed-author:SimontsMyriamM,
pubmed-author:TMC125-C203 Study Group,
pubmed-author:WoodfallBrianB,
pubmed-author:YeniPatrickP
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
969-78
|
|
pubmed:meshHeading |
pubmed-meshheading:18764771-Adult,
pubmed-meshheading:18764771-Aged,
pubmed-meshheading:18764771-Anti-HIV Agents,
pubmed-meshheading:18764771-CD4 Lymphocyte Count,
pubmed-meshheading:18764771-Dose-Response Relationship, Drug,
pubmed-meshheading:18764771-Double-Blind Method,
pubmed-meshheading:18764771-Female,
pubmed-meshheading:18764771-HIV Infections,
pubmed-meshheading:18764771-HIV-1,
pubmed-meshheading:18764771-Humans,
pubmed-meshheading:18764771-Male,
pubmed-meshheading:18764771-Middle Aged,
pubmed-meshheading:18764771-Pyridazines
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
|
|
pubmed:affiliation |
St. Paul's Hospital, University of British Columbia, Vancouver, Canada. drjm@cfenet.ubc.ca
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
